Crossmark

Efficacy and safety of MIN-101: A new drug for the treatment of negative symptoms in schizophrenia a 12-week randomized, double blind, placebo-controlled trial

Crossref DOI link: https://doi.org/10.1016/j.eurpsy.2017.01.2120

Published Online: 2020-03-23

Published Print: 2017-04

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Luthringer, R.
License Information

License valid from 2020-03-23

Text and Data Mining valid from 2017-04-01
More Information

This article is maintained by: Elsevier

Article Title: Efficacy and safety of MIN-101: A new drug for the treatment of negative symptoms in schizophrenia a 12-week randomized, double blind, placebo-controlled trial

Journal Title: European Psychiatry

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.eurpsy.2017.01.2120

Content Type: simple-article

Copyright: Copyright © 2017 Published by Elsevier Masson SAS

Document is current

Any future updates will be listed below